Clinical Locations
Huntsman Cancer Institute - Cancer Research North
Board Certification
|
American Board of Internal Medicine (Sub: Medical Oncology)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine
|
Patient Rating
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Dr Fitzgerald is one of the best
after all is said she has and continues to do all that is possible to save my life and give me the best possible chance of having a useful life in the future.
Obviously a well educated person who appears to think deeply on every question we raised. This goes for her support staff as well.
Dr. Fitzgerald inspires trust and exhibits a truly caring attitude toward me and my wife. I am lucky and glad to have her as my oncologist
Lindsey is very caring. She explained my cancer in great detail. Her team above and beyond to help me feel cared for and comfortable.
I am lucky to have Dr. Fitzgerald as my oncologist. She is very knowledgeable and patient with me. She always answers my questions which are many.
Dr. Fitzgerald was amazing to consult with. I wish I could be a close friend as she is to involved with my health and I felt honest to the point she was uncomfortable with giving the diagnoises. May God be with her in her personal life and work.
Dr Fitzgerald has been a wonderful Dr. to help me out with my cancer. She listens to what I say and explains why and what I need to do. She is a wonderful Dr.
She has a very caring attitude and listens to my words.
Dr Fitzgerald and all supporting staff are just the greatest people! So kind, caring and concerned. Everyone answers all questions in a manner that is easy to understand. Much much love for Clinic 2D/2E.
Love her!
She seemed very knowledgeable and interested in me as a person.
Dr. Fitzgerald is very a bright and knowledgeable physician that has been instrumental in taking care of my medical challenges. I consider myself lucky to be treated by such a caring professional. Thank you so much Doctor.
Dr. Lindsey Fitzgerald supports patient preferences through her clinical expertise.
Dr. Fitzgerald is the best of the best. She's a very good listener and makes sure we are comfortable with all the aspects of our care at Huntsman. She knows what she is doing and that is comforting. We feel confident and comforted in her care. That's important.
Doctor Fitzgearld and her staff are always so kind to me. I even get half a hug most of the time and I need the hugs Thanks
Amazing care provider
Dr. Fitzgerald and thorough and informative. She has a pleasant manner and cares about her patients.
Always open about my condition, making certain I understand the options.
Dr. Fitzgerald had clearly read my health history, reviewed prior test results, and listened to everything I said. She spent time with me to review recommendations and I trusted her knowledge and opinion.
She takes great interest in finding solutions to problems in a personal manner.
She has always answered all of my questions and and talked to me about my T PLL. Thanks!
She was very informative and wrote down everything she said.
Very impressed with my consultation with her
Dr. Lindsey Fitzgerald is a very compassionate & caring doctor. She listens to me & recommends The appropriate tests to be done before treating. I am very happy to have her for my Oncologist!
Dr Fitzgerald is a wonderful doctor. She is throrogh, explains everything clearly, and expresses a caring manner. She made me feel comfortable and important.
Dr. Lindsey is very nice and listened to me and explained things so I could understand.
Dr. Fitzgerald is a remarkable Dr. She was so knowledgable about my history and me as a person.
Dr, Fitsgerald is kind, detail oriented and tenacious...great qualities for her area of expertise.
An amazing doctor who truly listens and takes the time to answers questions. Highly recommended!
By far the best doctor I have seen with my CLL. Takes time to explain things to me and various treatment options. Helps a great deal when your cancer doctor talks to you and helps you understand the illness and various side effects.
She is knowledgeable, kind, considerate and very easy to speak to and with
Wonderful! She really cares!
Excellent at what she does¿..
extremely informed and knowledgeable.
Dr. Fitzgerald is a great doctor.
Dr Fitzgerald was called into a meeting and sent Brynn to fill in rather than having to reschedule.
I am fairly new to care with her, but I cannot say enough about how engaged and caring she and her staff have been. I feel great confidence in the Dr. and her team, which I believe is key.
She is the best
Dr Fitzgerald is always so kind and caring spending a lot of time with us to answer question and give suggestions. She is great
Dr. Fitzgerald has a very good ability to listen and explain the situation and options going forward. Very nice bedside manner so to speak.
I do not always trust Doctors, however my trust in her is complete in Dr Fitzgerald's ability to treat me and bring me back to health.
Dr. Fitzgerald took the time to explain in detail my current condition. She was very patient and made me feel like I was her only patient. Thank you!
Very caring and spends time so you understand everything
She explained everything very well. I totally understood everything and left with no questions that she could answer at this time.
You were so helpful and gracious to me. Thank you!
Dr Fitzgerald is awesome. She responded to me very quickly, even though I am a new patient for her. She was able to get me into the hospital that day and begin my chemo treatments the next day. Thank you, Dr Fitzgerald, for everything.
Great Doctor who anyone would feel comfortable having a difficult disease!
Excellent
She was nice and kind I am not totally done with her. Follow up 3 months after radiation in my eye
Very concerned about me as a individual with serious healthcare issues
Excellent knowledge about my form of lymphoma. Treats me as a whole person.
Great skill and care as a physician. I appreciate her compassion and attention to detail with my specific type of cancer.
Good Doctor, who care and spent time
Dr. Fitzgerald was was very congenial and interested in my questions. Her explanations were clear and precise. She was cheerful and appeared to be happy to see us. Our appointment went very well and we did not feel that it was rushed.???
She is tremendous!
Excellent! Very knowledgeable and very caring.
She listens to my concerns
Very good doctor that we have a great deal of confidence in her and the staff!
Dr Fitzgerald is the best doctor & person who is at this keeping me alive and me aware of the facts and options facing us.
Dr. Fitzgerald was awesome, as was her PA
She is a wonderful and well informed Dr. She absolutely has our best interests in mind.
Caring, competent, and professional. Overall, a pleasant experience.
She really listens to you.Glad I have her as my dr
She's really caring and knowledgeable. Leukemia is hard but she's definitively helped us maintain a very positive attitude.
Listened to my concerns and took my suggestions into consideration.
Dr Fitzgerald is professional and easy to talk to. She listens to my ?¿s and answers them and is very easy to understand and relate to.
Lindsay Fitzgerald takes the time to make sure all my questions are answered thoroughly. She is very kind and empathetic in addition to being knowledgable.
I wish that all doctors were like Lindsey Fitzgerald.
She is great. So easy to understand, patient and kind
She is terrific!
She listens, cares, and knows her medicine.
She knows her field and how to apply it to patients, like me.
Even though Dr. Fitzgerald has been my doctor for 5 months I have come to respect and listen to what she says and what I need to do. She is the best doctor that I can have.
I highly recommend Dr. Fitzgerald and trust her with my life. It's not often you find a physician that is so caring, compassionate, and listens to all of your needs.
Excellent caring health care professional
My experience with Huntsman began in 2021 and I was involved with 3 doctors. My radiation treatment is complete and I now have followup appts with Dr. Fitzgerald, my oncologist. I know some of my questions are varied but Dr. Fitzgerald always takes the time to discuss my health. I have every confidence in her knowledge and skill as a doctor but especially appreciate her personal time in our followup appointments.
Dr. Fitzgerald is very knowledgeable. She listens, answers questions and studies your history before meeting with you. I trust her and have had excellent results from my treatment.
She is an excellent doctor that really listens and takes the whole person into consideration when providing care
Very knowledgable in her field. Listens and makes suggestions. Willing to take the extra step in treatment ideas
Dr Fitsgerald is very knowledgeable and very caring.
Beyond excellent in every respect. Could not have been more pleased.
She is excellent. Explains everything very clearly and is so interested in her patients
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Assistant Professor (Clinical) |
|---|---|
| Academic Divisions |
Hematology & Hematologic Malignancies
|
| Board Certification |
American Board of Internal Medicine (Sub: Medical Oncology)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine
|
Education history
| Undergraduate | Geography and Biology - Dartmouth College | B.A. |
|---|---|---|
| Professional Medical | Medicine - Tufts University School of Medicine | M.D. |
| Residency | Internal Medicine - University of Utah School of Medicine | Resident |
| Fellowship | Hematology/Oncology - University of Utah School of Medicine | Fellow |
Selected Publications
Journal Article
- Lee, K.M., Stott, R.T., Zhao, G., SooHoo, J., Xiong, W., Lian, M.M., Fitzgerald, L., Shi, S., Akrawi, E., Lei, J., Deng, S., Yeh, H., Markmann, J.F., Kim, J.I. (2014). TGF-ß-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur J Immunol, 44(6), 1728-36.
- Kittai, A.S., Huang, Y., Gordon, M., Denlinger, N., Mian, A., Fitzgerald, L., Bishop, J., Nagle, S., Stephens, D.M., Jaglowski, S., Hill, B., Danilov, A.V. (2021). Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplant Cell Ther, 27(1), 46-52.
- Vardell, V.A., Ermann, D.A., Fitzgerald, L.A., Shah, H.R., Hu, B., Stephens, D.M. (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. Am J Hematol, 98(7), E172-E174.
- Major, A., Yu, J., Shukla, N., Che, Y., Karrison, T.G., Treitman, R., Kamdar, M., Haverkos, B.M., Godfrey, J., Babcook, M.A., Voorhees, T.J., Carlson, S.G., Gaut, D., Oliai, C., Romancik, J.T., Winter, A.M., Hill, B.T., Bansal, R., Villasboas, J.C., Nizamuddin, I.A., Karmali, R., Fitzgerald, L.A., Stephens, D.M., Pophali, P.A., Trabolsi, A., Schatz, J.H., Hu, M., Bachanova, V., Slade, M., Singh, N., Ahmed, N., McGuirk, J.P., Bishop, M.R., Riedell, P.A., Kline, J. (2023). Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions.(Epub ahead of print). Blood Adv.
- Geoffrey Shouse, Andy Kaempf, Max J. Gordan, Andy Artz, David Yashar, Audrey M. Sigmund, Gordon Smilnak, Steven Bair, Agrima Mian, Lindsey Fitzgerald, Amneet Bajwa, Samantha Jaglowski, Neil Bailey, Mazyar Shadman, Kirsh Patel, Deborah Stephens, Manali Kamdar, Brian Hill, Jordan Gauthier, Reem Karmali, Loretta J Nastoupil, Adam S. Kittai, Alexey B Danilo (2023). A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood advances, 2023(202301), 0016.
- Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clinical lymphoma, myeloma & leukemia, 24(2), 94-104.e6.
- Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032.
- Hansen AR, Vardell VA, Fitzgerald L (2023). Epidemiologic Characteristics, Treatment Patterns, and Survival Analysis of Plasmablastic Lymphoma in the United States: A SEER and NCDB Analysis. Clinical lymphoma, myeloma & leukemia,
- Melody M, Epperla N, Shouse G, Romancik JT, Allen PB, Moyo TK, Kenkre VP, Ollila TA, Fitzgerald LA, Hess BT, David KA, Herr MM, Odetola O, Lin AY, Moreira J, Ma S, Winter JN, Roy I, Stephens DM, Danilov AV, Shah NN, Barta SK, Cortese MJ, Cohen J, Gordon LI, Karmali (2024). Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy. Blood advances,
- Karmali R, Machhi R, Epperla N, Shouse G, Romancik JT, Moyo TK, Kenkre VP, Ollila TA, Fitzgerald LA, Hess BT, David KA, Roy I, Zurko JC, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin IA, Ma S, Moreira J, Winter JN, Pro B, Stephens DM, Danilov AV, Shah NN, Cohen JB, Barta SK, Torka P, Gordon L (2024). Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell NHL Treated with CAR-T. Blood advances, 8(10), 2592-2599.
- Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar M, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson SG, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade M, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline (2023). Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood advances, 7(16), 4528-4538.
- Karmali R, Shouse G, Torka P, Moyo TK, Romancik J, Barta SK, Bhansali R, Cohen JB, Shah NN, Zurko J, Kenkre VP, Hess B, Stephens DM, Fitzgerald L, Ollila T, Tabiti B, Roy I, Ma S, Winter J, Pro B, Moreira J, Danilov AV, David K, Gordon LI, Epperla (2025). Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy. Blood cancer journal, 15(1), 43.
- Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah H (2025). Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens. Clinical lymphoma, myeloma & leukemia,
- Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens DM, Romancik JT, Cortese MJ, Bhansali RS, Moyo TK, Kenkre VP, Ollila TA, Hess BT, Fitzgerald LA, Shouse G, Matasar MJ, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover NS, Karmali (2025). Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium. Blood advances,
- Melody M, Grover NS, Franco S, Romancik JT, Cortese MJ, Moyo TK, Bhansali RS, Ollila TA, Kenkre VP, Fitzgerald LA, Hess BT, Matasar MJ, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Lin AY, Danilov AV, Roy I, Barta SK, Gordon LI, Stephens DM, Cohen JB, Epperla N, Karmali (2025). Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium. Blood advances,
- Fitzgerald L, Ghosh S, Bokun A, Lax A, Mu F, Wu E, Lin Y, Shi L, Qureshi ZP, Graf S (2025). Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs. Journal of comparative effectiveness research, 14(11), e250084.
- Trabolsi A, Han S, Epperla N, Annunzio K, Baidoun F, Alhaj Moustafa M, Morgenstern-Kaplan D, Doukas P, St-Pierre F, McCall B, Fitzgerald L, Sandoval-Sus J, Dalal S, Reis IM, Chapman-Fredricks JR, Kim SH, Au C, Otto NB, Alhamad K, Ollila T, Karmali R, Shouse G, Lossos IS, Alderuccio J (2024). Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study. Blood neoplasia, 2(1), 100063.
- St-Pierre F, Bhatta S, Doukas PG, Jenkin M, Annunzio K, Rojek AE, Gibson A, Tiger YK, McCall B, Alhamad K, Hansen A, Alderuccio JP, Adewale O, Patel K, Trabolsi A, Lossos IS, Fitzgerald L, Ollila TA, Matasar MJ, Kline J, Karmali R, Epperla (2025). Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study. Blood cancer journal, 15(1), 110.
- Altomare NJ, Herr MM, Nair NM, Stephens DM, Cohen JB, Epperla N, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin A, Ma S, Winter JN, Danilov A, Barta SK, Gordon LI, Romancik J, Grover NS, Karmali R, American BiTE and CART Consortiu (2025). Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART. Cancers, 17(14),
- Fitzgerald L, Ghosh S, Khan W, Bokun A, Lax A, Mu F, Cook EE, Chen J, Chen G, Wu E, Lin Y, Shi L, Qureshi ZP, Graf S (2026). Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. Journal of managed care & specialty pharmacy, 32(2), 186-200.
- Sharp J, Strati P, Bhatta S, Huang JJ, Thomas CJ, Elghawy O, Reef D, Gorzewski AM, Wang JS, Shouse G, Reinert C, Teferra A, Toro Velez E, Pelcovits A, Ollila TA, Clark WB, Yazbeck V, Maakaron JE, Kamdar M, Fitzgerald LA, Danilov AV, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla (2026). Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study. Blood advances,
- Ermann D, Vardell V, Zacholski E, Fegley A, Modi D, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Ba Aqeel S, Borogovac A, MacDougall K, Kothari S, Kress A, Travers E, Chilakamarri N, Brem E, Ayyappan S, Sigmund A, Bond D, Fitzgerald L, Wagner C, Hu B, Stephens DM, Shah (2026). Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia,
- Wierda WG, Brown J, Abramson JS, Awan F, Bociek G, Boyer D, Cortese M, Cripe L, D'Angelo C, Darnell E, Davis RS, Eradat H, Esteghamat N, Fitzgerald L, Fletcher CD, Gaballa S, Huntington S, Kahl B, Kamdar M, Kipps TJ, Ma S, Mosse CA, Nakhoda S, Parikh SA, Riedell P, Schorr A, Schuster S, Seshadri M, Shanafelt T, Siddiqi T, Sitlinger A, Thompson M, Ujjani C, Wagner-Johnston N, Woyach JA, Dwyer M, Sundar (2026). NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026. Journal of the National Comprehensive Cancer Network, 24(3), 68-80.
Review
- Sindt JE, Fitzgerald LA, Kuznicki J, Prelewicz S, Odell DW, Brogan S (2023). Antiplatelet and Wound Healing Implications of Immunotherapy and Targeted Cancer Therapies in the Perioperative Period. Anesthesiology, 139(4), 511-522.
Case Report
- Fitzgerald, L., Stephens, D.M. (2020). Burkitt Lymphoma Presenting as Cranial Multineuritis Secondary to Primary Neurolymphomatosis: A Diagnostic Challenge. Clin Lymphoma Myeloma Leuk, 20(4), e201-e204.
Letter
- Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali (2023). Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. Journal of hematology & oncology, 16(1), 111.
- Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens D (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. American journal of hematology, 99(3), 494-496.
Abstract
- Imran, N.i.z.a.m.u.d.d.i.n., Kevin A., D.a.v.i.d., Jonathon B., C.o.h.e.n., Vaishalee P., K.e.n.k.r.e., Geoffrey, S.h.o.u.s.e., Brian T., H.e.s.s., Thomas A., O.l.l.i.l.a., Deborah M., S.t.e.p.h.e.n.s., Sayan Mullick, C.h.o.w.d.h.u.r., Robert, F.e.r.d.m.a.n., Kaitlyn'Shea, O.'.S.h.e.a., Jieqi, L.i.u., Jason T., R.o.m.a.n.c.i.k., Joanna C., Z.u.r.k.o., Rahul S., B.h.a.n.s.a.l.i., Elyse I., H.a.r.r.i.s., McKenzie, S.o.r.r.e.l.l., Rebecca, M.a.s.e.l., Lindsey, F.i.t.z.g.e.r.a.l.d., Carlos, G.a.l.v.e.z., Shuo, M.a., Jane N., W.i.n.t.e.r., Barbara, P.r.o., Leo I., G.o.r.d.o.n., Alexey V., D.a.n.i.l.o.v., Nirav N., S.h.a.h., Stefan K., B.a.r.t.a., Narendranath, E.p.p.e.r.l.a., Pallawi, T.o.r.k.a., Reem, K.a.r.m.a.l.i. (2023). Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. American Society of Hematology (ASH Publication) [Abstract]. Blood, (2021) 138 (Supplement 1)(532).
- Joanna C., Z.u.r.k.o., Narendranath, E.p.p.e.r.l.a., Imran, N.i.z.a.m.u.d.d.i.n., Pallawi, T.o.r.k.a., Kevin A., D.a.v.i.d., Thomas A., O.l.l.i.l.a., Brian T., H.e.s.s., Jonathon B., C.o.h.e.n., Robert, F.e.r.d.m.a.n., Jieqi, L.i.u., Sayan Mullick, C.h.o.w.d.h.u.r.y., Kaitlyn'Shea, O.'.S.h.e.a., Jason, R.o.m.a.n.c.i.k., Rahul, B.h.a.n.s.a.l.i., Elyse, H.a.r.r.i.s., Mckenzie, S.o.r.r.e.l.l., Rebecca, M.a.s.e.l., Lindsey, F.i.t.z.g.e.r.a.l.d., Carlos, G.a.l.v.e.z., Shuo, M.a., Jane N., W.i.n.t.e.r., Barbara, P.r.o., Leo I., G.o.r.d.o.n., Alexey V., D.a.n.i.l.o.v., Deborah M., S.t.e.p.h.e.n.s., Nirav N., S.h.a.h., Geoffrey, S.h.o.u.s.e., Vaishalee P., K.e.n.k.r.e., Stefan K., B.a.r.t.a., Reem, K.a.r.m.a.l.i. (2022). Outcomes and Treatment Patterns with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. American Society of Hematology (ASH) Annual Meeting [Abstract]. Blood, (2022)(140 (24)), 2584-2593.
- Geoffrey, S.h.o.u.s.e., Andy, K.a.e.m.p.f., David, Y.a.s.h.a.r., Audrey M., S.i.g.m.u.n.d., Gordon, S.m.i.l.n.a.k., Steven M., B.a.i.r., Agrima, M.i.a.n., Lindsey, F.i.t.z.g.e.r.a.l.d., Amneet, B.a.j.w.a., Samantha, J.a.g.l.o.w.s.k.i., Neil, B.a.i.l.e.y., Mazyar, S.h.a.d.m.a.n., Krish, P.a.t.e.l., Deborah M., S.t.e.p.h.e.n.s., Manali, K.a.m.d.a.r., Brian T., H.i.l.l., Jordan, G.a.u.t.h.i.e.r., Reem, K.a.r.m.a.l.i., Adam S, K.i.t.t.a.i., Alexey V., D.a.n.i.l.o.v. (2022). Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter Review Study. American Society of Hematology (ASH) Annual Meeting [Abstract]. Blood, (2022) 140(Supplement 1), 2048-2050.
- Geoffrey Shouse, Andy Kaempf, Max J. Gordan, David Yashar, Audrey M Sigmund, Gordon Smilnak, Steven M. Bair, Agrima Mian, Lindsey A. Fitzgerald, Amneet Bajwa, Samantha Jaglowski, Neli Bailey, Mazyar Shadman, Krish Patel, Deborah M. Stephens, Manali Kamdar, Brian T. Hill, Jordan Gauthier, Reem Karmali, Loretta J. Nastoupil, Adam S Kittai, Alexey V Danilo (2022). Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study. 140(Supplement 1), 2048-2050.
- Daniel A. Ermann, Victoria A. Vardell, Manasa Velagapudi, Greer Burkholder, Lindsey A. Fitzgerald, Mayur Narkhede, Harsh Shah, Lauren Shea, Adam Spivak, Deborah M. Stephens, Boyu Hu, Gaurav Goya (2022). Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy. 140(Supplement 1), 1076-1078.
- Ishan Roy, Narendranath Epperla, Geoggrey Shouse, Jason T. Romancik, Tamara K. Moyo, Vaishalee P, Kenkre, Thomas A. Ollila, Lindsey A. Fitzgerald, Brian T. Hess, Andrew M. Evens, Joanna Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S. Bhansali, Elyse I. Harris, McKenzie Sorrell, Jieqi Liu, Imran A. Nizamuddin, Jonathan Moreira, Shuo Ma, Jane N. Winter, Barabara Pro, Deborah M. Stephens, Alexy B Danilov, Mirav N. Shah, Jonathon B. Cohen, Stefan K. Barta, Pallawi Torka, Leo I. Gordon, Reem Karmal (2022). Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy. 140(Supplement 1), 2416-2418.
- Charlotte B Wagner, Daniel A. Ermann, Ken Boucher, Adrienne N. Nedved, Ivan N. Micallef, Sanjal H Desai, Haris Hatic, Gaurav Goyal, Erin Zacholski, Amanda Fegley, Audrey M. Sigmund, David A. Bond, Courtney Samules, Manali K Kamdar, Sheeba Ba Aqueel, Pallawi Torka, Kira MacDougall, Azra Borogovac, Sridevi Rajeeve, Suchitra Sundaram, Kalub Fedak, Dipenkumar, Modi, Elizabeth Travers, Sabarish Ayyappan, Nitin Chilakamarri, Elizabeth A Brem, Deborah M Stephens, Boyu Hu, Lindsey A. Fitzgerald, Harsh Sha (2022). Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival. 140(Supplement 1), 9390-9392.
- Deborah M. Stephens, Aaron Atkinson, James Jack Abbot, Marianne Bowling, Justin Williams. Tony D. Pomciter, Lindsey A. Fitzgerald, David Wad (2022). High Prevalence of Beta-Human Papilloma Virus in Patients with Concurrent Chronic Lymphocytic Leukemia and Non-Melanoma Skin Cancer. 140(Supplement 1), 7053.
- Victoria A. Vardell, Daniel A. Ermann, Harsh Shah, Lindsey A. Fitzgerald, Boyu Hu, Deborah M. Stephen (2022). T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments. 140(Supplement 1), 1085-1086.
- Joanna Zurko, Geoffrey Shouse, Pallawi Torka, Tamara K. Moyo, Jason T. Romancik, Imran A. Nizamuddin, Kaitlin Annunzio, Jieqi Liu, Stefan K. Barta, Robert Ferdman, Rahul Bhansali, Jonathon B. Cohen, Syan Mullick Chowdhurty, Nirav N. Shah, Elyse I. Harris, Vaishalee P. Kenkre, McKenzie Sorrell, Brian T. Hess, Deborah M. Stephens, Lindsey A. Fitzgerald, Thomas A. Ollila, Ishan Roy, Shuo Ma, Jane N. Winter, Barbara Pro, Jonathan Moreira, Leo I. Gordon, Alexey V Danilov, Andrew M. Evens, Narendranath Epperla, Reem Karmal (2022). Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy. 140(Supplement 1), 375-377.
- Daniel A Ermann, Victoria A. Vardell, Lindsey A. Fitzgerald, Harsh Shah, Boyu Hu, Deborah M. Stephens (2022). Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia. 140(Supplement 1), 6668-6669.
- Patel S, Esther J, Sama S, Fitzgerald (2022). From B to T: A case of concurrent B-cell and T-cell lymphomas successfully palliated with targeted therapies (2022). Association of VA Hematology/Oncology (AVAHO) National Meeting.
- Fitzgerald L, Sama S, Patel S, Ether (2022). Waldenstrom’s Macroglobulinemia presenting as Schnitzler’s Syndrome.
- Sama S, Fitzgerald L, Patel (2022). Not Just Castleman Disease: an elusive diagnosis of TAFRO syndrome. Association of VA Hematology/Oncology (AVAHO) National Meeting.
- Victoria Vardell, Daniel Arthur Ermann, Harsh Shah, Lindsey Fitzgerald, Boyu Hu, Deborah M Stephens (2022). Survival outcomes in patients with chronic lymphocytic leukemia treated at academic centers. 40(Supplement 16), 7544.